Cures Within Reach represented on Editorial Board of inaugural drug repurposing journal

CHICAGO - Feb. 28, 2014 - PRLog -- Cures Within Reach improves patient quality and length of life by facilitating Rediscovery Research^TM pilot clinical trials that repurpose existing drugs and devices for new uses. Awareness has been growing in recent years around drug repurposing as an affordable and effective treatment development process.  Evidence of this can be seen through the emergence of dedicated conferences around the globe, the NCATS initiative launched by the National Institutes of Health (NIH), increases in topical articles, and even in the research and development activity of forward-looking pharmaceutical companies.

Cures Within Reach will be represented on the journal’s Editorial Board by Cures’ President and Chief Science Officer, Dr. Bruce Bloom and Cures’ Science Advisory Board Co-chair, Dr. E Mitchell Seymour.

Dr. Bloom has been a part of Cures Within Reach since 2002, and at the helm since 2005.  He holds a Juris Doctor degree from Chicago Kent College of Law, a Doctor of Dental Surgery degree from University of Illinois Medical Center, and a Bachelor of Science degree in Biology from University of Illinois. He was faculty at Kendall College, has been a lecturer at the University of Illinois Chicago for 15 years, and was a senior lecturer at Northwestern University for 6 years. Dr. Bloom has taught Business Law and Risk Management to thousands of health care and other professionals since 1985. Dr. Bloom was elected an International Ashoka Fellow in 2009. Ashoka: Innovators for the Public recognizes social entrepreneurs for their system-changing solutions to the world's most urgent social problems.

Dr. Seymour began serving as a Science Advisor to Cures Within Reach in 2013.  He is research faculty at the University of Michigan Medical School and also serves in the Michigan Institute for Clinical and Health Research. In this unit, he assists faculty with their Investigational New Drug and Investigational New Device submissions to Food and Drug Administration (FDA). He also serves on their Institutional Review Board. As a freelance consultant, he provides regulatory affairs services for industry and academia. Regulatory experience includes US FDA regulatory writing and submissions, FDA meeting preparation and engagement, regulatory strategy, regulatory intelligence, and regulatory due diligence. As a life scientist, he has over 20 years of experience in basic science and clinical research in industrial and academic settings. He earned his BS in Biology from the University of Notre Dame and his PhD in Biochemical and Molecular Nutrition from Michigan State University. Dr. Seymour is active in the Drug Information Association, the Regulatory Affairs Professional Society, and the American Medical Writers Association. He has also earned the US Regulatory Affairs Certified credential from the Regulatory Affairs Professional Society.

Drug Repurposing, Rescue, and Repositioning is being launched by Mary Ann Liebert, Inc., a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals. The firm publishes over 80 journals, newspapers and books including Genetic Engineering & Biotechnology News (GEN), the first in its field and today the industry’s most widely read publication worldwide.  Drug Repurposing, Rescue, and Repositioning will include original papers, application-oriented technology reviews, and reports in methodology and technology application. Timely and authoritative articles will cover topics such as: assay design, target development, high-throughput technologies, and chemistry; lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis; approaches to assays configured for gene families, inherited, and infectious diseases; assays and strategies for adapting model organisms to drug discovery; the use of stem cells as models of disease; translation of phenotypic outputs to target identification; and exploration and mechanistic studies of the technical basis for assay and screening artifacts.

To learn more about Cures Within Reach: www.cureswithinreach.org

To learn more about the journal launch: http://www.liebertpub.com/global/pressrelease/drug-repurp...